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Abstract
Introduction: 1-Methylnicotinamide (MNA), a major metabolite of nicotinamide (NA), is known to exert anti-inflammatory
effects in vivo. Treatment of inflammatory skin diseases by topical application of MNA provides certain advantages over the
use of NA. However, in contrast to NA, the molecular mechanisms of the anti-inflammatory properties of MNA are not well
known. In this study the influence of exogenous MNA and NA in vitro on the generation of inflammatory mediators by
macrophages (Mφ) was investigated. 
Materials and Methods: Peritoneal Mφ of CBA/J mice were activated in vitro with lipopolysaccharide and incubated with
MNA or NA. The effect of these compounds on biological functions of Mφ was measured by evaluation of the production
of reactive oxygen species (ROS) by luminol-dependent chemiluminescence, cytokines and prostaglandin E2 (PGE2) by
ELISA, and nitric oxide (NO) by the Griess method. Moreover, the expressions of inducible NO synthase and cyclooxyge-
nase-2 were measured by Western blotting.
Results: It was shown that at non-cytotoxic concentrations, NA inhibits the production of a variety of pro-inflammatory
agents, such as tumor necrosis factor α, interleukin 6, NO, PGE2, and the generation of ROS. In contrast to NA, exogenous
MNA inhibited only the generation of ROS, while its effect on the synthesis of other mediators was negligible.
Conclusions: These results indicate that the anti-inflammatory properties of MNA demonstrated previously in vivo do not
depend on its capacity to suppress the functions of immune cells, but more likely may be related to its action on vascular
endothelium. The authors suggest that the limited permeability for exogenous MNA, in contrast to that for NA, may be
responsible for its lack of suppressor activity against Mφ.
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INTRODUCTION
1-Methylnicotinamide (MNA), a major metabolite
of nicotinamide (NA), has been shown recently to act in
vivo as a very efficient anti-inflammatory agent [9].
After topical application of MNA, a remarkable thera-
peutic effect was observed in such inflammatory skin
diseases as rosacea and acne vulgaris as well as in skin
burns and wound healing [22, 23]. On the other hand,
MNA therapy was not effective in cases with accompa-
nying bacterial infection, which indicates that
MNA’s therapeutic effectiveness is related to its anti-
-inflammatory, but not anti-bacterial, properties [1].
Moreover, it was demonstrated that MNA displays an
anti-thrombotic potential [3]. All these observations
contradict the common view that MNA is a biologically
inactive metabolite of NA [19]. However, in contrast to
NA, the mechanism of MNA’s anti-inflammatory activ-ity is still unclear. It remains to be examined whether
MNA is able to inhibit the functions of immune cells,
especially those involved in an inflammatory response
(Fig. 1).
NA (niacinamide) is the amide of nicotinic acid
(niacin, vitamin PP or B3) [4]. Over the years, NA has
been tried in the treatment of various diseases, such as
pellagra, psoriasis, diabetes, and schizophrenia [12, 21,
24]. In the last decade it has been shown that NA exerts
a number of anti-inflammatory properties, e.g. inhibi-
tion of the synthesis of pro-inflammatory cytokines
(tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6,
IL-8, interferon (IFN)-γ), inhibition of inducible nitric
oxide synthase (iNOS), modulation of free radical scav-
enging, and suppression of the expression of MHC class
II and some adhesion molecules on immune cells [10,
11, 13, 14, 16]. It has been suggested that the anti-
-inflammatory properties of NA are related to the inhi-
bition of NAD-dependent enzymes, such as poly(ADP-
-ribose) polymerase-1 [16, 20].
In this study we examined the anti-inflammatory
potential of both MNA and NA in vitro. We chose
macrophages (Mφ) as representative immune inflam-
matory cells, potential targets for MNA and NA. In our
experimental model, peritoneal murine Mφ activated in
vitro with lipopolysaccharide (LPS) were incubated with
MNA and NA and the anti-inflammatory potential of
the agents was estimated by their ability to inhibit the




Inbred CBA/J mice (8–10 weeks old) from the
Department of Immunology (Jagiellonian University
Medical College, Kraków, Poland) were used. The ani-
mals were kept in a constant-climate environment with
respect to the temperature (22±2°C), humidity
(50±10%), and daylight cycle (light 6 am–6 pm) and
were fed standard laboratory diet with water and food
ad libitum. All animal procedures conformed with the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and the experi-
mental procedures used in the present study were
approved by the local Jagiellonian University Ethics
Committee on Animal Experiments.
Measurement of MNA/NA concentration
LPS-stimulated Mφ (5×105) were cultured with
MNA or NA used at the non-cytotoxic concentrations of
10 and 4 mM, respectively. After 24 h the supernatant
and cells were collected separately. The cells were
rapidly washed three times to remove extracellular
MNA or NA and frozen until analysis. Fifty percent ace-
tonitrile in water was used for extraction. The protein
precipitate was removed by centrifugation and the
supernatants were freeze dried and reconstituted with
the initial mobile phase of the chromatographic system.
Samples were analyzed using a liquid-chromatography
mass-spectrometry system previously described else-
where in detail [18].
Macrophages
Peritoneal mouse Mφ were induced by an intraperi-
toneal injection of 1.0 ml of paraffin oil (Marcol 52,
Exxon, USA). The cells were collected 72 h later by
washing out the peritoneal cavity with 5 ml of phos-
phate-buffered saline solution (PBS) containing 5 U
heparin/ml (Polfa, Poland). The cells were centrifuged
and red blood cells were lysed by osmotic shock using
distilled water. Osmolarity was restored by addition of
twice-concentrated PBS. The presence of Mφ (85–90%)
was judged by cytochemical demonstration of nonspe-
cific esterase-positive mononuclear cells using α-naphtyl
acetate (Sigma, USA).
Cell viability
The effect of treatment on cell viability was assessed
by measuring lactic dehydrogenase (LDH) activity in
the culture supernatants with the use of the LDH
Cytotoxity Detection Kit (Takara Biomedicals, Japan)
and the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega, USA) according to the
manufacturers’ instructions. In accordance with statisti-
cal analysis (non-linear curve fitting), the nontoxic dose
ranges of NA and MNA were determined. A threshold
of 90% viable cells was established for testing.
Cell culture: activation of cells for the production 
of inflammatory mediators
Mφ stimulated with LPS (100 ng/ml) were incubated
with different concentrations of MNA or NA (1–30
mM) to test the possible anti-inflammatory activity of
the agents. Mφ were cultured in 96-well flat-bottom cell
culture plates at 1×105 cells/well in RPMI 1640 medium
supplemented with 5% fetal calf serum at 37°C in an
atmosphere of 5% CO2. After 24 h of culture the cells
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+and supernatants were collected and frozen at 80°C for
further analyses.
Determination of cytokines
Cytokine concentrations in culture supernatants
were measured using capture ELISA. For TNF-α, IL-6,
IL-10, and IL-12p40 determination, microtiter plates
(Corning, USA) were coated overnight with rat
mononuclear antibody (mAb) against a mouse cytokine
(capture antibody). After blocking the plates with 3%
non-fat dried milk (for IL-10: 4% albumin), the stan-
dards and tested supernatants were added and incubat-
ed overnight. The plates were then coated with biotiny-
lated antibodies against the same cytokine-detecting
antibody for 1 h. The ELISA was developed with horse-
radish peroxidase streptavidin (Vector, USA), followed
by o-phenylenediamine and H2O2 (both Sigma-Aldrich,
Germany) as substrates, incubated for 30 min. The reac-
tion was stopped with 3 M H2SO4 and the optical densi-
ty of each well was measured at 492 nm in a 96-well
plate reader. Recombinant murine cytokines were used
as standard agents. 0.05% Tween 20 in phosphate buffer
was used as a washing solution. 
The following reagents were used for the following
assays:
• IL-6: rat anti-mouse IL-6 and biotinylated rat anti-
-mouse IL-6 (both Pharmingen, USA) mAbs were
used as capture and detecting antibodies. Re-
combinant mouse IL-6 (PeproTech, USA) was used
as a standard. The detection limit was about 15 pg
IL-6/ml; 
• IL-10: rat anti-mouse IL-10 and biotinylated rat anti-
-mouse IL-10 mAbs were used as capture and
detecting antibodies. Recombinant mouse IL-10 was
used as a standard (all reagents from Pharmingen,
USA). The limit of detection was 15 pg IL-10/ml;
• IL-12 p40: rat anti-mouse IL-12 (p40/p70) clone 15.6
(Pharmingen, USA) mAb and biotinylated rat anti-
-mouse IL-12(p40) clone 17.8 (Endogen, USA) mAb
were used as capture and detecting antibodies.
Recombinant mouse IL-12 (Genzyme, UK) was
used as a standard. The detection limit was about 30 pg
IL-12 p40/ml; 
• TNF-α: hamster anti-mouse/rat TNF-α and biotiny-
lated rabbit anti-mouse/rat TNF-α (both Pharmin-
gen, USA) mAbs were used as capture and detecting
antibodies. Recombinant mouse TNF-α (Sigma,
Germany) was used as a standard. The limit of
detection was 30 pg TNF-α/ml;
• prostaglandin E2 (PGE2) immunoassay: PGE2 con-
centration in supernatants was determined using
a monoclonal antibody/enzyme immunoassay kit
from Cayman Chemical Co. according to the manu-
facturer’s instructions;
• nitrite determination: nitric oxide (NO), quantified
by the accumulation of nitrite as a stable end-prod-
uct, was determined by a microplate assay [6].
Briefly, 100-µl samples were removed from the
supernatants of the Mφ culture and incubated with
an equal volume of Griess reagent [0.35% 4-ami-
nophenyl sulfone (Sigma-Aldrich, Germany), 0.1%
N-(1-naphthyl)ethylenediamine dihydrochloride in
1M HCl (POCh, Poland)] at room temperature for
10 min. The absorbance at 550 nm was measured
and nitrite concentration was calculated from a sodi-
um nitrite standard curve.
Western blot analysis of iNOS and COX-2 expression
Mφ were cultured with different concentrations of
MNA and NA for 24 h and the expressions of iNOS and
cyclooxygenase-2 (COX-2) in cytosol were determined
by a Western blot technique. Briefly, after incubation
the cells were lysed in a lysis buffer (1% Triton X-100,
0.1% sodium dodecyl sulfate (SDS) in PBS) containing
a protease inhibitor cocktail (Sigma-Aldrich, Germany).
Protein concentrations of lysates were determined using
a bicinchoninic acid protein assay kit (Sigma-Aldrich,
Germany). Samples containing equal amounts of total
protein were mixed with gel loading buffer [0.125
M Tris, 4% SDS, 20% glycerol, 0.2 M DTT (dithiothre-
itol), 0.02% bromophenol blue] in a ratio 2:1 (v/v) and
boiled (4 min). Then the samples (20 µg of total protein
per lane) were separated on 10% SDS-polyacrylamide
gels (Mighty Small II, Amersham Biosciences, USA)
using a Laemmli buffer system and the proteins were
transferred to nitrocellulose membranes (Bio-Rad,
USA). Non-specific binding sites were blocked
overnight with 3% non-fat dried milk at 4°C and the
membranes were incubated for 2 h at room temperature
(RT) with rabbit polyclonal antibody to iNOS (1:2000)
(Stressgen, Canada) or rabbit polyclonal antibody to
COX-2 (1:1000) (Cayman, USA). Bands were detected
with alkaline phosphatase-conjugated secondary anti-
body (1 h at RT, 1:3000, Sigma-Aldrich, Germany) and
developed with BCIP/NBT alkaline phosphatase sub-
strate (Sigma-Aldrich, Germany). Additionally, mem-
branes were reprobed with monoclonal anti-β-actin
antibody (1 h at RT, 1:3000, Sigma-Aldrich, Germany).
Prestained SDS-PAGE Standards, Low Range (Bio-
-Rad, USA), were used for molecular weight determina-
tions. Protein bands were scanned and analyzed with the
freeware Scion Image (Scion Corporation, USA). The
data were normalized to the constitutively expressed 
β-actin protein.
Reactive oxygen species generation: 
luminol-dependent chemiluminescence assay
Chemiluminescence was tested at 37°C in a temper-
ature-stabilized Lucy 1 luminometer (Anthos, Austria).
Mφ (1×107 cells/ml) in Hank’s balanced salt solution
were preincubated (60 min at 37°C in an atmosphere of
5% CO2) on a 96-well flat-bottom black plate (Nunc,
Denmark) with luminol sodium salt (0.4 mg/ml; Sigma,
Germany) and with different concentrations of the
agents tested (1–30 mM). After incubation, the cells
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zymosan (0.4 mg/ml) and photon emission over 75 min
with 3-min intervals was measured. Each type of exper-
iment was performed in duplicate.
Statistics
The statistical significance of differences between
groups was analyzed using a factorial ANOVA
(Microsoft Excel) followed by the Student’s t-test, if
appropriate. A p-value less than 0.05 was considered
statistically significant.
RESULTS
Distribution of exogenous MNA and NA 
added to the culture of LPS-stimulated Mφ
To compare the cell-membrane permeability and
stability of MNA and NA in vitro, the compounds were
added to LPS-activated Mφ for 24 h. The final intracel-
lular (cell lysates) and extracellular (supernatants) lev-
els of MNA and NA were estimated and compared with
the initial concentrations of the compounds. As shown
in Table. 1, the concentration of NA in culture medium
decreased by about 20% with a concomitant increase in
the intracellular level. However, NA was not metabo-
lized to MNA by Mφ, as the concentration of MNA in
the culture was not elevated above the baseline (data
not shown). The ratio of the concentration of NA mea-
sured in the culture medium to its final concentration in
Mφ was 8.57. Under the same experimental conditions,
the concentration of exogenous MNA in culture medi-
um decreased after 24 h also by about 20% of the initial
value. However, the ratio of the MNA concentration in
the medium to the final concentration in Mφ was 35.8,
which is four times higher than the ratio for NA. This
may indicate a limited cell-membrane permeability for
MNA compared with NA. Further conversion of exoge-
nous MNA by Mφ to its metabolites 1-methyl-2-pyri-
done-5-carboxamide and 1-methyl-4-pyridone-5-car-
boxamide is unlikely to be significant since these com-
pounds remained below the detection limit of the
method (data not shown).
Effect of MNA and NA 
on reactive oxygen species generation: 
scavenging properties of MNA and NA
Luminol-dependent chemiluminescence (LCL)
observed during the respiratory burst of Mφ is common-
ly attributed to the production of reactive oxygen
species (ROS) [17]. Upon addition of opsonized
zymosan, macrophage LCL increased light emission 30
times over baseline. When either MNA or NA was
added to the reaction mixture, a dose dependent
decrease in LCL was observed for both reagents (Fig.
2). NA was more effective than MNA. However, prein-
cubation of the cells with either MNA or NA did not
affect LCL; therefore the generation of ROS was not
inhibited (data not shown). These results therefore indi-
cate scavenging properties of the agents. 
Effect of MNA and NA on the production of cytokines 
by LPS-stimulated Mφ
Stimulation of Mφ in vitro with LPS resulted in a pro-
nounced release of pro- and anti-inflammatory
cytokines. Addition of NA to cultured cells at the time
of activation resulted in a dose-dependent inhibition of
both pro-inflammatory cytokines (TNF, IL-6). NA at
concentrations below 10 mM did not significantly affect
the production of IL-12p40 and only slightly inhibited
the release of IL-10, an anti-inflammatory cytokine.
MNA, in contrast to NA, did not affect the release of
any of the cytokines tested (Fig. 3).
Effect of MNA and NA on the production of NO
by LPS- and IFN-γ-stimulated Mφ
In our experimental set-up, exposure of Mφ to LPS
and IFN-γ resulted in the generation of nitrite (~14
µM), the end product of NO oxidation. As shown in Fig.
4, NA inhibited the release of nitrite in a dose-depen-
dent manner. The highest non-cytotoxic concentration
of NA (10 mM) almost completely abrogated the gener-
ation of nitrite (Fig. 4A) without affecting the expres-
sion of iNOS (Fig. 4B). MNA at non-cytotoxic concen-
trations did not affect either nitrite release or the
expression of iNOS.
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Table. 1. Distribution of MNA and NA added to the culture of LPS-stimulated macrophages
Exogenous compounds (µM)a Final concentrationb The ratio of medium 
medium cytosol to cytosol concentration 
MNA (0.0) <0.1 <0.5 ND
MNA (10.000) 7991±461  223±32  35.8
NA (0.0) 9±1 47±3 ND
NA (4.000) 3598±87 420±26 8.57
aMNA or NA was added to the culture of LPS-stimulated Mφ at the concentrations indicated in brackets. bAfter 24 h, supernatant
and Mφ were collected separately and the concentrations of extracellular (medium) and intracellular (cytosol) MNA and NA
were measured as described in Materials and Methods. ND – not done.Effect of MNA and NA on prostaglandin synthesis
by LPS-stimulated Mφ
As shown in Fig. 5, NA, but not MNA, inhibited the
production of PGE2, a major COX-2-dependent prosta-
glandin produced by activated Mφ, in a dose-dependent
manner. However, Western blot analyses showed that
NA did not reduce the expression of COX-2. On the
other hand, a slight increase in COX-2 expression was
observed in cells incubated with MNA. 
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Fig. 2. Scavenging properties of MNA and NA. Mφ (1×106 cells/well) in Hank’s solution were preincubated (60 min at 37°C in an atmos-
phere of 5% CO2) on 96-well flat-bottom black plate with luminol sodium salt (0.4 mg/ml) and different concentrations of (A) MNA and
(B) NA (1–30 mM). After incubation the cells were stimulated with opsonized zymosan (0.4 mg/ml) and photon emission was measured.
Results are expressed as the percentage of ROS production by OZ-stimulated Mφ ±SEM diminished by that of non-stimulated cells. Each
bar represents the mean (±SEM) of three individual experiments. *p<0.05.
Fig. 3. Effect of MNA and NA on the production of cytokines by LPS-stimulated Mφ. Cells stimulated with LPS (100 ng/ml) were exposed
to MNA and NA in the culture medium for 24 h and then the content of cytokines in the medium was measured by ELISA. A – TNF-α, B –
IL-6, C – IL-12p40, D – IL-10. Results are expressed as the percentage of the cytokine production by control Mφ ±SEM. Data were calcu-
lated 5–8 separate experiments. *p<0.05.DISCUSSION
In the present study we showed that the stimulation
of peritoneal Mφ with LPS results in a massive secretion
of a variety of inflammatory mediators, such as TNF-α,
IL-6, IL-12p40, IL-10, NO, and PGE2. Incubation of
these cells with NA showed a dose-dependent reduction
of the synthesis of all the mediators tested. Especially
mediators with pro-inflammatory properties, such as
NO, IL-6, TNF-α, and PGE2 (the major eicosanoid pro-
duced by inflammatory phagocytic cells), were sup-
pressed. The production of IL-10, a cytokine with anti-
-inflammatory potential, was inhibited to a lesser
extend, which supports the anti-inflammatory proper-
ties of NA. These results are in agreement with previous
observations [7, 20]. For example, it has been shown that
NA is a potent inhibitor of pro-inflammatory cytokines
produced by cells of the innate immune system [20].
Moreover, it has been shown that NA, but not MNA,
inhibits cytokine synthesis, especially the synthesis of
TNF-α [5, 8, 15]. Collectively, all these observations
clearly indicate that the anti-inflammatory properties of
NA are related to its ability to down-regulate functions
of the cells of the immune system. However, the mech-
anism of anti-inflammatory activity of NA is still
unclear.
MNA, in contrast to NA, as shown in this study, does
not affect the functions of Mφ. Thus it seems to be
unlikely that the anti-inflammatory properties of MNA
demonstrated in vivo [22, 23] depend on the same mech-
anisms as those of NA. Examination of the therapeutic
potential of MNA in cardiovascular pharmacology pro-
vides some evidence and suggestions that a major target
for MNA at a site of inflammation seems to be endothe-
lium [3, 9]. Our investigations also support this hypoth-
esis. We recently demonstrated that exogenous, orally
administered MNA profoundly attenuates the contact
hypersensitivity reaction to oxazolone in mice through
endothelial PGI2-dependent mechanisms [2].
Therefore, the divergent biological activities of
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Fig. 4. Effect of MNA and NA on the production of NO and iNOS
expression by LPS plus IFN-γ-stimulated Mφ. Cells stimulated
with LPS (100 ng/ml) and IFN-γ (50 U/ml) were exposed to MNA
and NA in the culture medium for 24 h and then both the medium
and the cells were collected for further assay. A – the release of
nitrites (NO2
–); the results are expressed as the percentage of the
(NO2
–) production by control Mφ ±SEM. Data were calculated
from three separate experiments. B – the expression of iNOS; the
data are normalized to constitutively expressed β-actin protein
±SEM. Densitometric analysis of bands from two independent
experiments. *p<0.05.
Fig. 5. Effect of MNA and NA on the production of PGE2 and
COX-2 expression by LPS-stimulated macrophages. Cells stimu-
lated with LPS (100 ng/ml) were exposed to MNA and NA in the
culture medium for 24 h and then both the medium and the cells
were collected for further assays. A – the release of PGE2; results
are expressed as the percentage of the PGE2 production by control
Mφ ±SEM. Data were calculated from two separate experiments.
B – the expression of COX-2; the data are normalized to constitu-
tively expressed β-actin protein ±SEM. Densitometric analysis of
bands from two independent experiments. *p<0.05.MNA and NA in vitro and their similar anti-inflamma-
tory effect in vivo may be explained by the fact that dis-
tinct cells seem to be targets for MNA and NA.
Nevertheless, the mechanisms of the different effects of
exogenous MNA and NA on the functions of Mφ remain
to be explained. The present data show that Mφ are not
able to metabolize exogenous NA to MNA in vitro. This
clearly indicates that NA, but not its metabolites, is
responsible for the observed effects. Thus it is tempting
to speculate that the limited cell-membrane permeabili-
ty for MNA compared with that for NA may be respon-
sible for the lack of effect of MNA on the synthesis of
inflammatory mediators by activated Mφ. The results of
the LCL experiments also support the thesis that MNA
acts in the extracellular space, as it does not inhibit ROS
generation but acts as a scavenging agent. On the other
hand, it was found previously that MNA, but not NA,
can be bound to glycosaminoglycans located on the sur-
face of vascular endothelium cells without effective pen-
etration of the tissue, thus increasing its local concen-
tration on the cell surface [9]. 
All these observations, the lack of effect of MNA on
the synthesis of inflammatory mediators in vitro togeth-
er with the remarkable anti-inflammatory properties of
MNA in vivo as demonstrated in the experimental con-
tact hypersensitivity reaction in mice [2] and in the treat-
ment of contact dermatitis in humans [22, 23] suggest
that endothelial cells, but not immune cells, are the tar-
get for MNA. Thus in our opinion, MNA can be regard-
ed as an effective anti-inflammatory agent, the action of
which does not impair the immunity of patients.
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